{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:42:34Z","timestamp":1786653754551,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>A 49-year-old female with biopsy proven primary vitreoretinal lymphoma and primary central nervous system lymphoma (PCNSL) presented with asymmetric involvement of both eyes. Right eye had primarily retinal and optic nerve involvement with no light perception while the left eye had purely vitreal form of the disease with visual acuity of 6\/18. She was treated with recommended DeAngelis protocol for PCNSL and achieved complete remission of CNS disease and in the right eye and responded only partially to the systemic chemotherapy in the left eye. She received multiple intravitreal methotrexate injections (400 \u221dg\/0.1 ml) for persisting disease in the left eye. However, she developed resistance to the same after repeated injections for which therapeutic vitrectomy was performed. She achieved final visual acuity of 6\/12 in the right eye and 6\/18 in the left eye and did not relapse until last follow-up of 2 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0973-1482.140824","type":"journal-article","created":{"date-parts":[[2015,10,9]],"date-time":"2015-10-09T11:54:49Z","timestamp":1444391689000},"page":"668","source":"Crossref","is-referenced-by-count":21,"title":["Therapeutic vitrectomy for vitreal recurrence of intraocular lymphoma resistant to intravitreal methotrexate post systemic chemotherapy"],"prefix":"10.4103","volume":"11","author":[{"given":"Pradeep","family":"Venkatesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Gogia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Khanduja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satpal","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-139-20231126","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/09273940903370755","article-title":"Clinical review: Treatment of vitreoretinal lymphoma","volume":"17","author":"Pe'er","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"key":"R2-139-20231126","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J Clin Oncol"},{"key":"R3-139-20231126","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/08820530500350498","article-title":"Primary intraocular lymphoma: A review","volume":"21","author":"Choi","year":"2006","journal-title":"Semin Ophthalmol"},{"key":"R4-139-20231126","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/1097-0142(19930801)72:3<843::AID-CNCR2820720333>3.0.CO;2-#","article-title":"The clinical spectrum of ocular lymphoma","volume":"72","author":"Peterson","year":"1993","journal-title":"Cancer"},{"key":"R5-139-20231126","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1076\/ocii.8.4.243.6463","article-title":"Ocular and central nervous system lymphoma: Clinical features and diagnosis","volume":"8","author":"Cassoux","year":"2000","journal-title":"Ocul Immunol Inflamm"},{"key":"R6-139-20231126","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","article-title":"Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation therapy oncology group (RTOG): RTOG 8315","volume":"23","author":"Nelson","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-139-20231126","first-page":"711","article-title":"High-dose methotrexate for intraocular lymphoma","volume":"9","author":"Batchelor","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R8-139-20231126","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/107327480401100502","article-title":"Intraocular lymphoma: Update on diagnosis and management","volume":"11","author":"Chan","year":"2004","journal-title":"Cancer Control"},{"key":"R9-139-20231126","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/bjo.2007.127928","article-title":"Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience","volume":"92","author":"Frenkel","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R10-139-20231126","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0161-6420(93)31469-7","article-title":"Intraocular lymphoma. Clinical and histopathologic diagnosis","volume":"100","author":"Whitcup","year":"1993","journal-title":"Ophthalmology"},{"key":"R11-139-20231126","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.83.4.448","article-title":"Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma","volume":"83","author":"de Smet","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"R12-139-20231126","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.1999.17.4.1326c","article-title":"Intraocular methotrexate level after high-dose intravenous infusion","volume":"17","author":"Henson","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201511030-00139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:55Z","timestamp":1786650115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201511030-00139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.140824","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}